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Abstract: 1,8-cineole, a monoterpenoid is a major component of eucalyptus oil and has been proven 
to possess numerous beneficial effects in humans. Notably, 1,8-cineole is the primary active ingre-
dient of a clinically approved drug, Soledum® which is being mainly used for the maintenance of 
sinus and respiratory health. Due to its clinically valuable properties, 1,8-cineole has gained signif-
icant scientific interest over the recent years specifically to investigate its anti-inflammatory and 
antioxidant effects. However, the impact of 1,8-cineole on the modulation of platelet activation, 
thrombosis and haemostasis was not fully established. Therefore, in this study, we demonstrate the 
effects of 1,8-cineole on agonists-induced platelet activation, thrombus formation under arterial 
flow conditions and haemostasis in mice. 1,8-cineole largely inhibits platelet activation stimulated 
by glycoprotein VI (GPVI) agonists such as collagen and cross-linked collagen-related peptide 
(CRP-XL), while it displays minimal inhibitory effects on thrombin or ADP-induced platelet aggre-
gation. It inhibited inside-out signalling to integrin αIIbβ3 and outside-in signalling triggered by 
the same integrin as well as granule secretion and intracellular calcium mobilisation in platelets. 
1,8-cineole affected thrombus formation on collagen-coated surface under arterial flow conditions 
and displayed a minimal effect on haemostasis of mice at a lower concentration of 6.25 µM. Notably, 
1,8-cineole was found to be non-toxic to platelets up to 50 µM concentration. The investigation on 
the molecular mechanisms through which 1,8-cineole inhibits platelet function suggests that this 
compound affects signalling mediated by various molecules such as AKT, Syk, LAT, and cAMP in 
platelets. Based on these results, we conclude that 1,8-cineole may act as a potential therapeutic 
agent to control unwarranted platelet reactivity under various pathophysiological settings. 
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1. Introduction 
Cardiovascular diseases (CVD) specifically thrombotic conditions such as ischemic 
stroke and heart attacks are the leading cause of death around the modern world. Platelets 
are small anucleated circulating blood cells and they play an essential role in the mainte-
nance of haemostasis through blood clotting upon vascular injury [1]. However, the inap-
propriate activation of platelets during pathological conditions such as upon the rupture 
of atherosclerotic plaque results in the formation blood clots (thrombi) within the vascu-
lature leading to reduced/blocked blood supply to vital organs such as the heart and brain. 
Therefore, platelets act as a powerful therapeutic target to prevent/treat thrombotic dis-
eases and indeed, anti-platelet drugs such as aspirin and clopidogrel play predominant 
roles in the treatment, management, and prevention of these conditions. However, the 
currently available anti-platelet drugs present serious side effects such as gastrointestinal 
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toxicity, bleeding, and tolerance in some patients. Hence, there is an unmet clinical need 
for more effective and safer anti-platelet drugs to prevent and treat thrombotic diseases 
[2]. 
Naturally available small molecules derived from plants have remained as a major 
source of active pharmaceutical ingredients for drug discoveries [3]. While the impact of 
a broad spectrum of flavonoids on the modulation of platelet activation has been estab-
lished in detail, the research on the modulatory effects of terpenoids on platelets is limited. 
Essential oils are volatile plant secondary metabolites containing a complex mixture of 
monoterpenoids, sesquiterpenoids and other oxygenated hydrocarbons [4,5]. They play 
critical roles in many industries such as to produce cosmetics, perfumes, food materials 
and pharmaceuticals [6,7]. Essential oils from various plants possess numerous chemicals 
with therapeutic effects such as anti-inflammatory properties [8]. 1,8-cineole (also known 
as ‘eucalyptol’), a principal constituent of eucalyptus oil has been increasingly used in 
medical applications due to its wider pharmacological effects [9,10]. Chemically, it is a 
bicyclic monoterpene [11] and has been reported to possess anti-inflammatory, antimicro-
bial and antioxidant effects in several pathological conditions [12]. Indeed, 1,8-cineole is 
the active ingredient of Soledum®, a clinically approved medication for the treatment of 
respiratory tract diseases [12,13]. Some in vitro studies have shown that 1,8-cineole exhib-
its anti-inflammatory activity by inhibiting the production of certain cytokines in mono-
cytes when stimulated with lipopolysaccharides (LPS) [14]. 1,8-cineole is also able to re-
duce hypersecretion of mucus in airways during asthma [14]. Furthermore, 1,8-cineole 
inhibits the activities of specific pro-inflammatory mediators of NF-κB-signalling by pre-
venting the nuclear translocation of p65 [15]. Intrigued by the broad range of beneficial 
effects of 1,8-cineole, here, we demonstrate its effects in the modulation of platelet activa-
tion, thrombus formation and haemostasis. 
2. Results 
2.1. 1,8-Cineole Largely Inhibits Platelet Aggregation Induced by GPVI Agonists 
To determine the impact of 1,8-cineole on the modulation of platelet activation, ag-
gregation assays were performed using various agonists. Human isolated platelets (4 × 
108 cells/mL) were incubated with a vehicle control [0.01% (v/v) ethanol] or various con-
centrations of 1,8-cineole (6.25 µM–100 µM) for five minutes prior to stimulation with dif-
ferent concentrations of GPVI agonists such as collagen and cross-linked collagen-related 
peptide (CPR-XL). At higher concentrations (50 and 100 µM), 1,8-cineole significantly in-
hibited (by around 50–70%) 1 µg/mL collagen-activated platelet aggregation (Figure 
1A,B). However, when the concentration of collagen was reduced to 0.5 µg/mL, 1,8-cine-
ole displayed significant inhibitory effects at all the concentrations used (Figure 1C,D). 
Notably, 100 µM of 1,8-cineole has completely inhibited collagen-induced platelet aggre-
gation, while the other concentrations have shown around 30–80% inhibition. Since colla-
gen binds to both GPVI and integrin α2β1 receptors to activate platelets, a selective ago-
nist for GPVI, CRP-XL was then used to determine the precise effects of 1,8-cineole via 
this receptor. Similar to collagen, CRP-XL (1 µg/mL) induced platelet aggregation was 
largely reduced by higher concentrations of 1,8-cineole (Figure 1E,F), although at a lower 
(0.5 µg/mL) concentration of CRP-XL, all the concentrations of 1,8-cineole inhibited plate-
let aggregation in a concentration-dependent manner (Figure 1G,H). 




Figure 1. Effect of 1,8-cineole on GPVI agonists-stimulated aggregation in human isolated platelets. 
A vehicle control [0.1% (v/v) ethanol] or various concentrations of 1,8-cineole were incubated with 
human isolated platelets for 5 min prior to stimulation of aggregation with 1 µg/mL (A,B) or 0.5 
µg/mL (C,D) collagen, and 1 µg/mL (E,F) or 0.5 µg/mL (G,H) CRP-XL. The level of aggregation was 
monitored for 5 min in an optical aggregometer. The aggregation traces shown are representative 
of five separate experiments. The percentage of aggregation for 1,8-cineole-treated samples was cal-
culated by considering the level of aggregation obtained with the vehicle control (0) as 100%. Data 
represent mean ± SEM (n = 5). The p values shown (* p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 
0.0001) are as calculated by one-way ANOVA followed by Bonferroni post hoc test. 
Following the determination of the inhibitory effects of 1,8-cineole on isolated plate-
lets, its effects in the modulation of platelet activation was determined in the presence of 
plasma proteins using human platelet-rich plasma (PRP). Similar to its effects in isolated 
platelets, 1,8-cineole did not show large effects on 1 µg/mL collagen (Figure 2A,B) and 
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CRP-XL (Figure 2E,F)-induced platelet aggregation. However, when the concentration of 
collagen (Figure 2C,D) and CRP-XL (Figure 2G,H) was reduced to 0.5 µg/mL, 1,8-cineole 
inhibited platelet aggregation at all the concentrations tested. 
 
Figure 2. Impact of 1,8-cineole on GPVI agonists-stimulated aggregation in human PRP. Human 
PRP was treated with a vehicle control [0.1% (v/v) ethanol] or various concentrations of 1,8-cineole 
for 5 min prior to stimulation of aggregation with 1 µg/mL (A,B) or 0.5 µg/mL (C,D) of collagen, 
and 1 µg/mL (E,F) or 0.5 µg/mL (G,H) of CRP-XL. The level of aggregation was monitored for 5 min 
by optical aggregometry. The aggregation traces shown are representative of five separate experi-
ments. The percentage of aggregation for 1,8-cineole-treated samples was calculated by considering 
the level of aggregation obtained with the vehicle control (0) as 100%. Data represent mean ± SEM 
(n = 5). The p values shown (* p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001) are as calculated 
by one-way ANOVA followed by Bonferroni post hoc test. 
Furthermore, to analyse if 1,8-cineole is able to inhibit platelet aggregation induced 
by agonists that stimulate platelet activation via G-protein-coupled receptors (GPCRs), 
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aggregation assays using thrombin in human isolated platelets (4 × 108 cells/mL) and ADP 
in human PRP were performed. Except at a concentration of 100 µM, 1,8-cineole did not 
affect thrombin (0.1 U/mL) (Figure 3A,B) induced platelet aggregation. However, when 
the concentration of thrombin was reduced to 0.025 U/mL, 1,8-cineole inhibited platelet 
aggregation at 25 µM and above (Figure 3C,D). ADP (Figure 3E–H)-induced platelet ag-
gregation was not affected by 1,8-cineole at any of the concentrations used except a small 
(around 20–30%) inhibition observed at 100 µM when lower concentration (2.5 µM) of 
ADP was used. Together, these results suggest that 1,8-cineole mainly inhibits platelet 
aggregation induced by collagen and CRP-XL although at higher concentrations it affects 
other agonists-induced platelet activation. 
 
Figure 3. Effect of 1,8-cineole on thrombin- and ADP-stimulated aggregation in human platelets. 
Human isolated platelets were incubated with a vehicle control [0.1% (v/v) ethanol] or various con-
centrations of 1,8-cineole for 5 min prior to stimulation of aggregation with 0.1 U/mL (A,B) or 0.025 
U/mL (C,D) thrombin. Similarly, human PRP was incubated with various concentrations of 1,8-
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cineole for 5 min prior to inducing platelet aggregation with 5 µM (E,F) or 2.5 µM (G,H) ADP. The 
level of aggregation was monitored for 5 min by optical aggregometry. The aggregation traces 
shown are representative of four separate experiments. The percentage of aggregation for 1,8-cine-
ole-treated samples was calculated by considering the level of aggregation obtained with the vehicle 
control (0) as 100%. Data represent mean ± SEM (n = 4). The p values shown (* p < 0.05, ** p < 0.01 
and *** p < 0.001) are as calculated by one-way ANOVA followed by Bonferroni post hoc test. 
2.2. Inside-Out Signalling to Integrin αIIbβ3 Is Affected by 1,8-Cineole 
Platelet aggregation is dependent on the conformational changes to integrin αIIbβ3 
(a highly abundant platelet surface receptor [16]) induced by inside-out signalling in 
platelets in order to transform the receptor from a low-affinity state to a high affinity bind-
ing state for fibrinogen and von Willebrand factor (vWF) [16,17]. Therefore, to determine 
the effect of 1,8-cineole on this critical event, the level of fibrinogen binding as a marker 
for inside-out signalling to integrin αIIbβ3 was measured in platelets upon stimulation 
with CRP-XL (0.5 µg/mL), thrombin (0.025 U/mL) and ADP (2.5 µM). 1,8-cineole showed 
significant reduction in the level of fibrinogen binding in both human isolated platelets (4 
× 108 cells/mL) (Figure 4A) and PRP (Figure 4B) upon stimulation with CRP-XL at all the 
concentrations used. However, when thrombin (in isolated platelets) and ADP (in PRP) 
were used as agonists, 1,8-cineole inhibited fibrinogen binding only at a higher concen-
tration (50 µM). These results demonstrate that 1,8-cineole is able to affect the inside-out 
signalling to integrin αIIbβ3, and thereby controls the level of fibrinogen binding on the 
platelet surface and subsequent platelet aggregation. 
 
Figure 4. Effect of 1,8-cineole on inside-out signalling to integrin αIIbβ3 in human platelets. Human 
isolated platelets (IP) or PRP were incubated with a vehicle control [0.01% (v/v) ethanol] or various 
concentrations of 1,8-cineole for 5 min prior to addition of CRP-XL (0.5 µg/mL) (A,B), thrombin 
(0.025 U/mL) (C) or ADP (2.5 µM) (D) and further incubation for 20 min at room temperature. The 
level of fibrinogen binding (as a marker for inside-out signalling to integrin αIIbβ3) on the platelet 
surface was quantified using FITC-conjugated anti-human fibrinogen antibodies by flow cytometry. 
The bar graph indicates the percentage of fibrinogen binding as calculated with respect to the vehi-
cle (0) control (considered as 100%). Data represent mean ± SEM. (n = 5). The p values shown (* p < 
0.05, ** p < 0.01 and *** p < 0.001) are as calculated by one-way ANOVA followed by Bonferroni post 
hoc test. 
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2.3. 1,8-Cineole Affects Granule Secretion in Platelets 
Platelets release several effector molecules from their granules upon stimulation with 
agonists to augment platelet activation and thrombus formation [18]. Platelets contain dif-
ferent granules such as α-granules, dense granules, and lysosomes. α-granules stores 
mainly proteins such as fibrinogen, vWF and P-selectin, whereas small organic molecules 
such as ADP, ATP and serotonin are stored in dense granules [19,20]. Hence, the effect of 
1,8-cineole on α-granule secretion in platelets was assessed by measuring the level of P-
selectin exposure on the platelet surface upon stimulation with CRP-XL (0.5 µg/mL), 
thrombin (0.025 U/mL) and ADP (2.5 µM) using flow cytometry. The level of P-selectin 
exposure was significantly reduced in the presence of 1,8-cineole at all concentrations 
(6.25 µM–50 µM) tested in human isolated platelets (4 × 108 cells/mL) (Figure 5A) and at 
concentrations between 12.5 µM–50 µM in human PRP (Figure 5B) when CRP-XL was 
used. While thrombin (Figure 5C) or ADP (Figure 5D) was used, 1,8-cineole inhibited P-
selectin exposure only at a higher concentration of 50 µM. Similarly, the effect of 1,8-cin-
eole on dense granule secretion upon platelet activation was analysed by measuring the 
level of ATP secretion using lumi-aggregometer. Human isolated platelets (4 × 108 
cells/mL) were incubated with luciferase-luciferin chrono-lume reagent in the presence 
and absence of different concentrations of 1,8-cineole prior to stimulation with CRP-XL 
(0.5 µg/mL) to measure the level of ATP released. Indeed, 1,8-cineole has displayed sig-
nificant inhibitory effects on dense granule secretion at all the concentrations tested (Fig-
ure 5E,F). These results demonstrate the effects of 1,8-cineole on the modulation of granule 
secretion in platelets. 
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Figure 5. Impact of 1,8-cineole on granule secretion in human platelets. Human isolated platelets 
(IP) or PRP were incubated with a vehicle control [0.01% (v/v) ethanol] or various concentrations of 
1,8-cineole for 5 min prior to the addition of CRP-XL (0.5 µg/mL) (A,B), thrombin (0.025 U/mL) (C) 
or ADP (2.5 µM) (D) and further incubation for 20 min at room temperature. The level of α-granule 
secretion in platelets was determined by quantifying the amount of P-selectin exposed (as a marker 
for α-granule secretion) on the platelet surface upon activation using PE/Cy5-conjugated anti-hu-
man P-selectin antibodies by flow cytometry. The bar graphs show the effects of various concentra-
tions of 1,8-cineole on α-granule secretion in human isolated platelets or PRP upon stimulation with 
different agonists. Moreover, the effect of 1,8-cineole on dense granule secretion was quantified by 
measuring the level of ATP release upon activation of platelets. The human isolated platelets were 
incubated with different concentrations of 1,8-cineole or a vehicle control [0.01% (v/v) ethanol] for 5 
min in the presence of the Chrono-lume luciferin-luciferase reagent and the level of ATP released 
upon platelet activation with 0.5 µg/mL CRP-XL was monitored using lumi-aggregometry. The 
traces (E) shown are representative of four separate experiments. The cumulative data (F) shown 
demonstrate the effect of 1,8-cineole on dense granule secretion in platelets as calculated by consid-
ering the level of ATP release observed with the vehicle control as 100%. Data represent mean ± 
SEM. (n = 4). The p values shown (* p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001) are as 
calculated by one-way ANOVA followed by Bonferroni post hoc test. 
2.4. 1,8-Cineole Inhibits Intracellular Calcium Mobilisation in Platelets 
Calcium is a critical mediator of platelet activation, and its levels are largely increased 
in platelet cytoplasm via release from intracellular stores (dense tubular system) and in-
flux from plasma [21]. Therefore, the impact of 1,8-cineole on the mobilisation of intracel-
lular calcium levels was analysed using Fluo 4-calcium sensitive dye in human PRP or 
isolated platelets (for thrombin) (4 × 108 cells/mL) upon activation with CRP-XL (0.5 
µg/mL), thrombin (0.025 U/mL) or ADP (2.5 µM) by spectrofluorimetry. The pre-incuba-
tion of platelets with different concentrations of 1,8-cineole has affected the peak calcium 
level in platelets upon stimulation with CRP-XL (Figure 6A,B). When thrombin (0.025 
U/mL) (Figure 6C,D) or ADP (2.5 µM) (Figure 6E,F), the level of calcium was only affected 
to a smaller extent (around 20%) by higher concentrations of 1,8-cineole. These results 
demonstrate that 1,8-cineole can affect the intracellular calcium mobilisation which is a 
critical event during platelet activation and subsequent thrombus formation. 




Figure 6. Effect of 1,8-cineole on intracellular calcium mobilisation in human platelets. Human PRP 
(A,E) or isolated platelets (C) treated with Fluo-4 AM dye were incubated with a vehicle control or 
various concentrations of 1,8-cineole for 5 min prior to stimulation of calcium release with CRP-XL 
(0.5 µg/mL) (A,B), thrombin (0.025 U/mL) (C,D) or ADP (2.5 µM) (E,F). The level of calcium release 
was monitored for 3 min by spectrofluorimetry. The traces shown are representative of four separate 
experiments. The cumulative data were calculated by taking the peak calcium released in the vehicle 
control as 100%. Data represent mean ± SEM. (n = 4). The p values shown (* p < 0.05 and ** p < 0.01) 
are as calculated by one-way ANOVA followed by Bonferroni post hoc test. 
2.5. Integrin αIIbβ3-Mediated Outside-In Signalling Is Affected by 1,8-Cineole 
Integrin αIIbβ3-mediated outside-in signalling plays critical roles to induce platelet 
spreading and at a later stage, clot retraction to facilitate wound healing [22,23]. To deter-
mine the effect of 1,8-cineole on the outside-in signalling mediated by integrin αIIbβ3, 
platelet spreading on fibrinogen-coated glass surface and the clot retraction assay were 
performed. Human isolated platelets (2 × 107 cells/mL) were incubated with different con-
centrations (6.25 µM–50 µM) of 1,8-cineole prior to adding them to human fibrinogen-
coated glass cover slips and allowing them to spread for 45 min. The analysis of confocal 
microscopy images demonstrates that 1,8-cineole significantly affects the number of plate-
lets adhered on fibrinogen-coated surfaces (Figure 7A,Bi). At the concentration of 50 µM 
of 1,8-cineole, only a small number of platelets were able to adhere to fibrinogen. 
Cells 2021, 10, 2616 10 of 22 
 
 
However, the progression of adhered platelets to filopodia formation and complete 
spreading was not affected by 1,8-cineole (Figure 7Bii), which may be due to significantly 
less adhered platelets in 1,8-cineole treated samples compared to the controls. To deter-
mine the impact of 1,8-cineole on clot retraction, human PRP was incubated various con-
centrations of 1,8-cineole (6.25–50 µM) prior to initiating clot formation by the addition of 
1 U/mL thrombin. The rate of clot retraction was monitored over 2 h by taking images at 
every 30 min. The effect of 1,8-cineole on clot retraction was analysed by measuring the 
remaining clot weight after 2 h. As expected, the clot size was completely retracted in the 
vehicle control, whereas the clot retraction was reduced in 1,8-cineole-treated samples 
with significant reduction observed at 12.5 µM and above (Figure 7C). Together, these 
data suggest that 1,8-cineole is able to influence integrin αIIbβ3-mediated outside-in sig-
nalling in platelets. 
 
Figure 7. Effect of 1,8-cineole on integrin αIIbβ3-mediated outside-in signalling in human platelets. Human isolated plate-
lets (at a density of 2 × 107 cells/mL) were incubated with a vehicle control (0) or different concentrations of 1,8-cineole for 
5 min and added onto fibrinogen- (100 µg/mL) coated coverslips and allowed them to spread for 45 min. Following fixation 
with 0.2% (v/v) formyl saline followed by permeabilisation with 0.2% (v/v) Triton X-100, the platelets were stained with 
Alexa Fluor 488-conjugated phalloidin for visualisation. Platelet spreading was analysed using a 100× oil immersion lens 
on a Nikon A1-R confocal microscope. Ten random images of view were recorded and for each sample, random locations 
on the slides were analysed. The number of platelets at different stages of spreading was determined by analysing the 
images using ImageJ. (A) representative images captured at 45 min of platelet spreading in the absence and presence of 
different concentrations of 1,8-cineole. (Bi) the cumulative data showing the number of platelets adhered to fibrinogen in 
control and 1,8-cineole treated samples. (Bii), the relative percentage of adhered platelets that progressed to filopodia and 
full spread stages on fibrinogen at 45 min. Data represent mean ± SEM (n = 4 individual experiments using platelets ob-
tained from four volunteers, and for each, 10 images were used for analysis). (C) to determine the impact of 1,8-cineole on 
clot retraction, human PRP was treated with various concentrations of 1,8-cineole prior to addition of 1 U/mL thrombin 
and monitoring of clot retraction for 2 h. The images shown are representative of four separate experiments. The data 
shown were calculated by measuring the remaining clot weights after 2 h of retraction. Data represent mean ± SEM (n = 
4). The p values shown (* p < 0.05, ** p < 0.001 and *** p < 0.001) are as calculated by one-way ANOVA followed by Bonfer-
roni post hoc test. 
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2.6. 1,8-Cineole Reduces Thrombus Formation under Arterial Flow Conditions 
Platelet aggregation following vascular injury culminates in thrombus formation in 
order to seal the damaged area and prevent bleeding [1]. To determine the impact of 1,8-
cineole on whole blood (i.e., in the presence of other blood cells and plasma proteins), 
thrombus formation on collagen-coated Vena8 biochips was analysed under arterial flow 
conditions. DiOC6-labelled human whole blood was incubated with various concentra-
tions of 1,8-cineole prior to infusion over collagen-coated capillaries in Vena8 biochips 
and the level of thrombus formation was monitored for 10 min by taking images at every 
30 s. 1,8-cineole at concentrations of 6.25 µM, 12.5 µM and 50 µM significantly inhibited 
the platelet adhesion, thrombus growth, volume (Figure 8A) and the fluorescence inten-
sity (Figure 8B) of thrombi formed. These data suggest that 1,8-cineole is able to affect 
platelet activation and subsequent thrombus formation in whole blood as similar to their 
inhibitory effects in isolated platelets and PRP. 
 
Figure 8. Impact of 1,8-cineole on thrombus formation and haemostasis. DiOC6 (a lipophilic dye) (5 
µM)-labelled human whole blood was incubated with a vehicle or different concentrations of 1,8-
cineole for 5 min and perfused through microfluidic channels (Vena8 BioChips) coated with colla-
gen (400 µg/mL). Thrombus formation was observed using a 20× objective on a Nikon A1-R confocal 
microscope, with images captured every 30 s up to 10 min (A). Quantified data represent median 
fluorescence intensity of thrombi formed at 10 min in control and 1,8-cineole-treated samples as 
calculated using NIS elements software (Nikon) and normalised to the level of median fluorescence 
intensity obtained for thrombi at 10 min in the vehicle treated sample (B). Data represents mean ± 
SEM (n = 3). The p values (* p < 0.05, and ** p < 0.01) shown are as calculated by one-way ANOVA 
with Dunnett’s post hoc test. (C) Effect of 1,8-cineole on haemostasis in mice was analysed using a 
tail bleeding assay. Mice (n = 6 per group) were anaesthetised and a vehicle control [0.01% (v/v) 
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ethanol] or 1,8-cineole (6.25 µM or 12.5 µM) was administered via femoral artery. After 5 min of 
incubation, 3 mm of tail tip was dissected, and the tail tip was placed in sterile PBS. The time for 
cessation of bleeding was measured up to 20 min. Data represent mean ± SEM (n = 6). The p values 
shown (** p < 0.01 and *** p < 0.001) are as calculated by non-parametric Kruskal–Wallis test. (D) To 
determine whether 1,8-cineole exerts any cytotoxic effects on human platelets, human isolated plate-
lets were exposed to a positive control, a vehicle control [0.1% (v/v) ethanol] or various concentra-
tions of 1,8-cineole for 30 min and the amount of LDH released (a marker for cytotoxicity) was 
measured at 490 nm and 650 nm using spectrophotometry. The maximum LDH release obtained 
with the positive control was taken as 100% and the level of LDH release for 1,8-cineole treated 
samples was calculated accordingly. Data represent mean ± SEM (n = 3). The p value shown (* p < 
0.05) was calculated by one-way ANOVA with post hoc Dunnett’s test. 
2.7. 1,8-Cineole Affects Haemostasis in Mice 
Haemostasis is a normal physiological response of the body to prevent excessive 
bleeding upon vascular injury [24]. To investigate the effect of 1,8-cineole on haemostasis, 
a tail-bleeding assay was performed in mice in the presence of a vehicle control or various 
concentrations (6.25 µM and 12.5 µM) of 1,8-cineole. Following the clipping of 3 mm tail 
tip, the bleeding time was monitored. The vehicle-treated mice bled for around 300 s, 
whereas the administration of 1,8-cineole extended the bleeding time to around 500 s at 
6.25 µM and 800 s with 12.5 µM (Figure 8C). These results indicate that 1,8-cineole affects 
the haemostasis in mice even at a low concentration of 6.25 µM to a modest level. 
2.8. 1,8-Cineole Is Not Cytotoxic to Platelets at Lower Concentrations 
Finally, to determine whether 1,8-cineole pharmacologically inhibits platelet activa-
tion, or it exerts any cytotoxic effects, lactate dehydrogenase (LDH) cytotoxicity assay was 
performed. Human isolated platelets (4 × 108 cells/mL) were incubated with different con-
centrations of 1,8-cineole (6.25 µM–100 µM) along with a positive control, and the amount 
of LDH released was measured as a marker for cytotoxicity using a spectrophotometer. 
1,8-cineole was found to be non-toxic up to 50 µM concentration, however, a low level of 
cytotoxicity was observed at 100 µM concentration (Figure 8D). This result indicates that 
the inhibitory effects of 1,8-cineole up to 50 µM are due to its pharmacological effects in 
platelets rather than its cytotoxicity. However, caution should be taken when 1,8-cineole 
is used at or above 100 µM as it is likely to cause cytotoxicity at these concentrations. 
2.9. 1,8-Cineole Affects Various Signalling Pathways in Platelets 
1,8-cineole has been reported to modulate various signalling pathways (e.g., cytokine 
production and NF-κB activity) that are involved in inflammatory responses [14,15]. Here, 
as 1,8-cineole largely inhibited GPVI-mediated platelet activation, the effect of 1,8-cineole 
on the phosphorylation of key downstream proteins in GPVI signalling pathway was in-
vestigated using human isolated platelets (4 × 108 cells/mL) by immunoblot analysis. 1,8-
cineole affected the phosphorylation of Syk (Figure 9A) and LAT (Figure 9B), which are 
key regulators of GPVI signalling pathway. Then, the impact of 1,8-cineole on the phos-
phorylation of AKT, which is a critical downstream effector molecule of phosphoinositide 
3 kinase (PI3K) signalling was evaluated. Indeed, 1,8-cineole inhibited the phosphoryla-
tion of AKT at all the concentrations tested (Figure 9C). To determine the impact of 1,8-
cineole on mitogen-activated protein kinase (MAPK) signalling pathways, the phosphor-
ylation of p38 and ERK1/2 was analysed using immunoblots. Similar to other signalling 
proteins, 1,8-cineole affected the phosphorylation of both p38 (Figure 9D) and ERK1/2 
(Figure 9E) at all the concentrations tested. To further explore the other targets for 1,8-
cineole in platelets, the level of cAMP was measured in the absence and presence of vari-
ous concentrations of this molecule without an agonist. 1,8-cineole has increased the level 
of cAMP (Figure 9F) and the phosphorylation of VASP which is a substrate for cAMP-
dependent protein kinase (PKA) (Figure 9G). Together, these data demonstrate that 1,8-
cineole is able to affect not only GPVI signalling pathway, but also it influences MAPK 
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and cAMP-mediated signalling in platelets. However, we cannot rule out the possibility 
of its impact on other signalling molecules/pathways in platelets as it may target multiple 
pathways in platelets. 
 
Figure 9. Effect of 1,8-cineole on specific signalling proteins and cAMP levels in platelets. Human isolated platelets (4 × 
108 cells/mL) were treated with a vehicle control (0) or various concentrations of 1,8-cineole for 5 min before stimulation 
with CRP-XL (0.5 µg/mL) for 5 min in an aggregometer at 37 °C. Then, the cells were lysed using reducing sample treat-
ment buffer and analysed in SDS-PAGE followed by immunoblots using various phospho-specific antibodies. The impact 
of 1,8-cineole on the phosphorylation of pSyk (Y525/526) (A), pLAT (Y200) (B), pAKT (S473) (C), pp38 (D), and pERK1/2 
(E) was analysed using selective phospho-specific antibodies for these proteins in immunoblots. (F) the level of cAMP in 
platelets that were treated with a vehicle control or various concentrations of 1,8-cineole was measured using a cAMP 
ELISA kit in line with the manufacturer’s instructions. Data represent mean ± SEM. (n = 4). (G) the phosphorylation of 
VASP (S157) was analysed using platelets that were treated with a vehicle control or different concentrations of 1,8-cineole. 
The level of 14-3-3ζ was detected as a loading control in all these blots. The blots shown are representative of three separate 
experiments. Data represent mean ± SEM (n = 3), normalised to loading control. The p values shown (* p < 0.05, ** p < 0.01 
and *** p < 0.001) are as calculated by one way-ANOVA followed by Bonferroni’s correction for multiple comparisons. 




Over the last few decades, extensive research has been performed on medicinal 
plants to identify and develop new drugs with reduced side effects for various human 
diseases [3]. Since platelets act as a powerful therapeutic target to control thrombotic dis-
eases [2], numerous plant-derived small molecules have been tested to determine their 
ability to inhibit platelet activation and thrombosis without any adverse effects on hae-
mostasis. Indeed, flavonoids such as quercetin [25,26], catechin [27,28], tangeretin [29] and 
nobiletin [30,31] were extensively studied for their inhibitory effects in platelets. However, 
research on investigating the anti-platelet effects of essential oils that contain terpenoids 
is highly limited. Notably, essential oils and their chemical constituents have shown to 
exhibit various pharmacological effects [5]. For example, eugenol, a major component of 
clove oil has been reported to inhibit the oxidation of low-density lipoproteins thereby it 
reduces the development of atherosclerosis [32]. α-curcumene, a major constituent of tur-
meric essential oil exerts triglyceride-lowering activity on serum as well as liver triglycer-
ides [33]. Interestingly, the essential oil from lavender has been reported to inhibit platelet 
aggregation induced by agonists such as collagen, ADP, arachidonic acid and U46619 [34]. 
1,8-cineole is a major active component of eucalyptus oil and thymus herb-derived essen-
tial oils [12]. 1,8-cineole has previously been shown to possess numerous beneficial effects 
including antioxidant and anti-inflammatory properties [12,13]. However, the effects of 
1,8-cineole on the modulation of platelet function have remained largely unexplored. 
Hence, in this study, the ability of 1,8-cineole to inhibit platelet activation and thrombus 
formation was investigated. 
Similar to several flavonoids [29,30] and eugenol [35], 1,8-cineole inhibits platelet ac-
tivation induced by agonists such as collagen and CRP-XL. A concentration-dependent 
inhibition of 1,8-cineole was observed in aggregation assays that were performed with 
human isolated platelets upon stimulation with CRP-XL and collagen. These effects were 
largely present when human PRP was used although a small reduction in their activities 
was observed. The binding of small molecules to plasma proteins was previously reported 
for various plant-derived compounds [29,36]. For example, tangeretin a flavonoid rich in 
lemon peel [29] and quercetin which is abundant in red onions [37] were shown to bind 
plasma proteins to an extent. Therefore, the binding of 1,8-cineole to plasma proteins may 
reduce its bioavailability. While the level of inhibition observed with the low concentra-
tions of 1,8-cineole was prominent when collagen and CRP-XL were used as agonists, it 
only inhibited thrombin or ADP-induced platelet aggregation at higher concentrations. 
When the concentration of thrombin was reduced, the effect of 1,8-cineole was more 
prominent at 25 µM and above. Similar to our findings with 1,8-cineole, eugenol (from 
nutmeg oil) was found to inhibit collagen-induced platelet aggregation with reduced ef-
fects on ADP- and thrombin-induced aggregation [35,38]. Another study has demon-
strated that the essential oil of cloves in which eugenol was a major component, inhibits 
collagen-induced platelet aggregation but was not able to cause a significant inhibition on 
ADP-induced platelet aggregation [39]. The essential oil of lavender has been reported to 
inhibit platelet aggregation induced by collagen, thromboxane receptor agonist (U46619), 
arachidonic acid and ADP on PRP [34]. In the same study, the antiplatelet effect of the 
main components of lavender essential oil [linalyl acetate (36.2%), linalool (33.4%), cam-
phor (7.6%) and 1,8-cineole (5.8%)] were also investigated [34]. The inhibitory effects of 
1,8-cineole observed on platelet aggregation in our study are also similar to the effects 
observed with several naturally occurring flavonoids including tangeretin [29] and nobi-
letin [30]. These observations strongly indicate that 1,8-cineole may mainly affect GPVI-
induced platelet activation pathway, although its effects on other pathways may be min-
imal. 
The stimulation of platelets by agonists induce inside-out signalling that transforms 
the conformation of the extracellular domain of integrin αIIbβ3 resulting in an increase in 
its binding affinity for plasma fibrinogen to facilitate aggregation [16]. As similar to ag-
gregation, 1,8-cineole inhibits the level of fibrinogen binding on platelet surface induced 
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by CRP-XL and other agonists. This indicates its ability to affect inside-out signalling to 
integrin αIIbβ3 which results in reduced platelet aggregation. Moreover, 1,8-cineole in-
hibited both α- and dense granule secretion in platelets upon stimulation with agonists. 
As components released from dense granules (e.g., ADP) and α-granules (e.g., vWF and 
fibrinogen) are essential regulators of secondary activation of platelets and thrombus for-
mation [20], this inhibition by 1,8-cineole suggests its ability to suppress the positive feed-
back cascades that lead to a rapid and large activation of platelets during thrombus for-
mation. Similar to 1,8-cineole, other essential oils such as elemicin and eugenol isolated 
from Cymbopogon ambiguus are volatile monoterpenoids with potent anti-inflammatory 
effects [40]. Both elemicin and eugenol have been reported to possess anti-platelet effects 
by inhibiting ADP-induced secretion of serotonin in human platelets. Eugenol exhibited 
potent inhibitory activity on ADP-induced platelet aggregation compared to aspirin [40]. 
Another study has demonstrated the inhibitory effects of eugenol on human PRP aggre-
gation induced by arachidonic acid, ADP and collagen with prominent inhibitory effects 
on arachidonic acid-induced platelet aggregation [41]. They also suggested that eugenol 
has an inhibitory effect on cyclooxygenase (COX) activity by inhibiting thromboxane A2 
production similar to aspirin. In addition, 1,8-cineole has affected intracellular calcium 
mobilisation in platelets. The elevation of calcium levels through release from intracellular 
stores and entry from outside via influx mechanisms is critical during platelet activation 
[21]. However, 1,8-cineole has shown to affect the calcium levels following agonists-in-
duced platelet activation suggesting that it may affect platelet reactivity at multiple stages. 
Integrin αIIbβ3-mediated outside-in signalling amplifies a range of cellular events 
that are essential for platelet functions such as spreading and clot retraction [23]. 1,8-cin-
eole significantly inhibited the adhesion of platelets (with no effects of filapodia formation 
and complete spreading) on fibrinogen-coated surface and clot retraction. Platelet spread-
ing is critical to allow platelet adhesion at the injury site and to provide surface for clotting 
cascades to take place, which finally results in generation of thrombin, another powerful 
activator of platelets [42]. The effect of 1,8-cineole on platelet spreading is similar to sev-
eral other flavonoids including tangeretin [29], nobiletin [30] and chrysin [43]. The clot 
retraction is another assay where the significance of integrin αIIbβ3-mediated outside-in 
signalling can be assessed [44]. The retraction process of the fibrin mesh is primarily 
driven by integrin αIIbβ3 which facilitates the interaction between fibrinogen bound on 
the surface of platelets and myosin-actin cytoskeleton inside the platelets [23]. 1,8-cineole 
inhibited clot retraction with increasing clot weights when concentrations were increased. 
Likewise, essential oil of lavender inhibited the clot retraction induced by thrombin in 
PRP [34]. Similar to 1,8-cineole, other essential oils such as oils of Ocotea quixos [45] and 
Foeniculum vulgare [46] reduced the clot retraction rate indicating their significance in in-
tegrin αIIbβ3-mediated outside-in signalling. 
The inhibition of numerous functions associated with platelet activation by 1,8-cine-
ole suggests its ability to subsequently modulate thrombus formation. Therefore, the im-
pact of 1,8-cineole on whole human blood was investigated by in vitro thrombus for-
mation assay under arterial flow conditions. Indeed, 1,8-cineole reduced thrombus for-
mation significantly by inhibiting platelet adhesion, thrombi number and volume over 
time. In contrast to other assays where isolated platelets or PRP were used, here the whole 
blood was used. Hence, this demonstrates the ability of 1,8-cineole to inhibit platelet func-
tion in the presence of plasma proteins and other blood cells. The prolonged exposure of 
this compound to platelets in the circulation may cause modest inhibition over time to 
prevent the unwarranted activation of platelets. Finally, the impact of 1,8-cineole on the 
modulation of haemostasis in mice was determined by tail bleeding assay. Here, 1,8-cin-
eole (at 12.5 µM and 6.25 µM) has shown to moderately extend the bleeding time in mice, 
which reflects the interaction between platelets and damaged blood vessel, leading to the 
formation of a haemostatic plug. Furthermore, the effect of 1,8-cineole on bleeding time 
could also be due to its vasodilation effects as reported in a previous study [47]. However, 
the impact of 1,8-cineole on the modulation of haemostasis in humans under diverse 
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pathophysiological scenarios should be investigated. Interestingly, 1,8-cineole was found 
to be non-cytotoxic to platelets up to 50 µM, and only a concentration of 100 µM has 
caused a mild (significant) toxic effect although this is a supraphysiological concentration 
which may not be achieved therapeutically. 
The molecular mechanistic studies indicated that 1,8-cineole may have multiple tar-
gets in platelets as similar to several other plant-derived small molecules. 1,8-cineole in-
hibits the phosphorylation of Syk and LAT which are involved in GPVI signalling path-
way [48]. This may reflect on the inhibitory effects of 1,8-cineole selectively on collagen 
and CRP-XL-induced platelet activation. During clot retraction process, the initial binding 
of cytoskeletal myosin depends on the phosphorylation of integrin β3 subunit with im-
portant downstream roles of Src and PLCγ2 [49]. The inhibitory effects of 1,8-cineole on 
clot retraction can be through the decreased activity of PLCγ2 and Src-family kinase. Fur-
thermore, it inhibits the phosphorylation of AKT at Serine 473, which is a downstream 
effector molecule of PI3K that plays a key role in platelet activation [50]. A previous study 
has shown that 1,8-cineole inactivates AKT in mice that exhibit hepatic lesions analogous 
to non-alcoholic steatohepatitis where the levels of AKT are upregulated [51]. Studies 
have indicated that 1,8-cineole inactivates AKT and survivin in human colon cancer cell 
lines [52] and it inhibits GSK-3 in nasal polyps in patients with chronic rhinosinusitis [53]. 
Previous studies that were aimed to investigate the anti-inflammatory activity of 1,8-cin-
eole have also indicated that 1,8-cineole interferes with various signalling pathways 
[14,15]. For example, in human umbilical vein endothelial cells (HUVECs), it has reported 
that 1,8-cineole mainly mediates its inhibitory effects via the NF-κB signalling pathway 
resulting in the suppression of pro-inflammatory cytokine release induced by bacterial 
LPS. Moreover, 1,8-cineole has shown to inhibit MAPKs specifically p38 and ERK1/2 
which are also critically important to regulate various cellular events in platelets [54]. In-
terestingly, 1,8-cineole increased the level of cAMP in platelets in the absence of an ago-
nist. The increased level of cAMP was also observed in platelets when treated with differ-
ent flavonoids [29]. The increase in cAMP levels by 1,8-cineole is likely due to its direct 
effects on adenylate cyclase (which regulates cAMP production) or phosphodiesterase 
(PDE), which controls the levels of cAMP in platelets to maintain them under resting con-
ditions in circulation [2]. Together, these data demonstrate that 1,8-cineole inhibits platelet 
activation via various signalling pathways. Although this study has investigated various 
aspects of platelet activation using 1,8-cineole, the complete understanding of its mecha-
nisms of action was not established in this single study. Therefore, further studies are re-
quired to establish the complete landscape of the mechanisms through which 1,8-cineole 
modulate platelet activation and its impact under pathological circumstances (using ani-
mal models and/or blood samples obtained from human patients with CVD). Moreover, 
the impact of 1,8-cineole in the modulation of thrombosis and haemostasis under in vivo 
conditions in mice and humans should be investigated in future to demonstrate its clinical 
applications. 
4. Materials and Methods 
4.1. Materials Used 
The clinical grade (99%) 1,8-cineole (C80601) and all other regular chemicals were 
purchased from Sigma Aldrich, UK. Horm collagen (Nycomed, Austria), CRP-XL (ob-
tained from Prof. Richard Farndale at the University of Cambridge), thrombin (T6884) and 
ADP (01905) (Sigma Aldrich, UK) were used as platelet agonists in this study. Fluo-4 NW 
calcium assay (F36206) and LDH cytotoxicity assay kits (88953) were purchased from 
ThermoFisher Scientific, UK. Vena8 biochips were obtained from Cellix Limited, Ireland. 
12 weeks old mice purchased from Envigo, UK were used for tail bleeding assay. The 
phosphospecific antibodies [pVASP S157 (3111S), pAKT S473 (4058S), pP38 T180/Y182 
(4511S) and pSyk Y525/526 (2711S)] and anti-14-3-3ζ (sc-293415) used in this study were 
from Cell Signalling technology and Santacruz Biotechnology, respectively. Similarly, 
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pLAT Y200 (ab68139) and pERK1/2 (ab201015) were obtained from Abcam, UK. The Cy5 
labeled anti-rabbit (A10523) and Cy3 labeled anti-mouse (A10521) antibodies were ob-
tained from ThermoFisher Scientific, UK. 
4.2. Platelet Preparation 
The preparation of human platelets was performed using standard protocols as de-
scribed previously [43,55]. All the experiments were performed in accordance with rele-
vant institutional and national guidelines. A written informed consent was obtained from 
human volunteers according to the procedures approved by the University of Reading 
Research Ethics Committee (UREC 17/17). The blood was drawn from healthy, aspirin-
free human volunteers via venipuncture into vacutainers containing 3.2% (w/v) sodium 
citrate as an anticoagulant. 
Platelet-rich plasma (PRP) preparation: Blood samples were centrifuged at 102 g for 
20 min at 20 °C. The resultant supernatant (PRP) was collected and rested for 30 min at 30 
°C prior to using them in aggregation, flow cytometry and clot retraction assays. 
Preparation of isolated platelets: 50 mL of whole blood was mixed with 7.5 mL of 
ACD [acid citrate dextrose; 20 g/L glucose, 25 g/L sodium citrate and 15 g/L citric acid] 
and centrifuged at 102 g for 20 min at 20 °C. The supernatant (PRP) was aspirated and to 
this 3 mL of ACD and 10 µL of prostaglandin I2 (PGI2) (125 µg/mL) were added prior to 
centrifuging at 1413 g for 10 min at 20 °C. The resulting platelet pellet was washed by 
resuspending in modified Tyrodes-HEPES buffer (25 mL) [2.9 mM KCl, 134 mM NaCl, 
0.34 mM Na2HPO4·12H2O, 1 mM MgCl2, 12 mM NaHCO3, 20 mM HEPES, pH 7.3] in the 
presence of 10 µL of PGI2 (125 µg/mL) and centrifuging at 1413 g for 10 min. The resulting 
platelet pellet was finally resuspended in modified Tyrodes-HEPES buffer at a density of 
4 × 108 cells/mL and rested for 30 min before use in aggregation, flow cytometry and im-
munoblot assays. 
4.3. Preparation of 1,8-Cineole 
Clinical grade 1,8-cineole was diluted in modified Tyrodes-HEPES buffer with 5% 
ethanol to the desirable concentrations for assays and the final concentration of ethanol in 
platelets was maintained at 0.01% (v/v). A vehicle control [ethanol at a concentration of 
0.01% (v/v)] was included in all the experiments and this concentration did not affect the 
platelet function. 
4.4. Aggregation and ATP Release Assays 
Platelet aggregation assays were performed using optical aggregometer (Chrono-
Log, USA) as described by us previously [55,56]. Platelets (445 µL) were incubated with 
different concentrations of 1,8-cineole or a vehicle control [0.01% (v/v) ethanol] (5 µL) for 
5 min at 37 °C. The samples were then activated with 50 µL of different concentrations of 
ADP, collagen, CRP-XL or thrombin and the level of platelet aggregation was monitored 
for 5 min. 
ATP release was determined as a measure for dense granule secretion in platelets 
using the luciferin-luciferase reagent by lumi-aggregometry (Chrono-Log, USA). Briefly, 
platelets (395 µL) were incubated with Chrono-Lume reagent (50 µL) for 2 min at 37 °C. 
After this, 5 µL of various concentrations of 1,8-cineole was added and incubated was for 
5 min prior to activation with 50 µL of agonist as stated above. 
4.5. Flow Cytometry-Based Assays 
The human isolated platelets or PRP were incubated with different concentrations of 
1,8-cineole or a vehicle control for 5 min in the presence of FITC-labelled anti-human fi-
brinogen antibodies (Dako, UK) and PECy5-labelled CD62P (P-selectin) antibodies (BD 
Biosciences, UK). Platelets were then activated with CRP-XL (0.5 µg/mL), ADP (2.5 µM 
using PRP) or thrombin (0.025 U/mL using isolated platelets) for 20 min at room 
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temperature. Following this, 0.2% (v/v) formyl saline was added to fix the platelets and 
the levels of fibrinogen binding (a marker for inside-out signalling to integrin αIIbβ3) and 
P-selectin exposure (a marker for α-granule secretion) were measured by flow cytometry 
(Accuri C6, BD Biosciences, UK). The median fluorescence intensity was used to assess 
the levels of fibrinogen binding and P-selectin exposure on the platelet surface. The level 
of fluorescence obtained with the vehicle control was taken as 100% to calculate the levels 
of fibrinogen binding and P-selectin exposure in 1,8-cineole treated samples. 
4.6. Calcium Mobilisation 
The intracellular calcium levels in platelets were measured using Fluo-4 AM calcium-
sensitive dye (Life Technologies, UK), which binds free intracellular calcium. 2 mL of hu-
man PRP (or isolated platelets for thrombin) were loaded with 2 mL (2 µM final concen-
tration) of Fluo-4 AM and incubated for 45 min at 30 °C in the dark. The isolated platelets 
or PRP loaded with Fluo-4 AM were incubated with a vehicle control [(0.01% (v/v) etha-
nol] or different concentrations (6.25, 12.5, 25, and 50 µM) of 1,8-cineole before activating 
with 0.5 µg/mL CRP-XL, ADP (2.5 µM) or thrombin (0.025 U/mL). The level of fluores-
cence intensity was measured by a Fluostar Optima plate reader (BMG Labtech, Germany) 
at 37 °C for 5 min using an excitation wavelength of 480 nm, and emission at 520 nm. The 
data were analysed by measuring the percentage of the maximum level of calcium was 
released in all the samples. 
4.7. Clot Retraction Assay 
Human PRP (200 µL) and red blood cells (5 µL) were mixed with modified Tyrodes-
HEPES buffer in the presence and absence of various concentrations of 1,8-cineole to a 
final volume of 950 µL and incubated for 5 min. Then, 50 µL thrombin (1 U/mL) was 
added to initiate clot formation. A blunt glass capillary was placed inside the tube around 
which the clot was formed, and the clot retraction was monitored over a period of 2 h at 
room temperature. After 2 h, the remaining clot weight was measured as a marker for clot 
retraction. 
4.8. In Vitro Thrombus Formation 
Human whole blood was incubated with 5 µM of a lipophilic dye, DiOC6 (3,3′-Di-
hexyloxacarbocyanine Iodide) (Sigma Aldrich, UK) at 30 °C for 30 min. Vena8 BioChip 
(Cellix Ltd., Ireland) microfluidic channels were coated with collagen (400 µg/mL) for one 
hour. Following blocking with 1% (w/v) bovine serum albumin for one hour, the human 
whole blood pre-incubated with a vehicle control or various concentrations (6.25, 12.5 and 
50 µM) of 1,8-cineole for 5 min was perfused through the collagen-coated microfluidic 
channels at a shear stress of 20 dynes/cm2 for 10 min. The level of thrombus formation was 
observed using a Nikon A1-R confocal microscope using 20× objective. Fluorescence im-
ages of thrombi were captured every 30 s continuously for 10 min. The median fluores-
cence intensity of thrombi was calculated using NIS Elements software (Nikon, Tokyo, 
Japan) and the images were analysed using ImageJ software (National Institute of Health, 
USA). 
4.9. Tail Bleeding Assay 
This experiment has been approved by the University of Reading Research Ethics 
Committee and the British Home Office (PPL 7709063). Briefly, 12 weeks old C57BL/6 mice 
(Envigo, UK) were anaesthetised [using ketamine (80 mg/kg) and xylazine (5 mg/kg)] via 
intraperitoneal route and the mice were placed on a heated pad (37 °C). After 20 min, a 
vehicle control [0.01% (v/v) ethanol] or 1,8-cineole (12.5 µM and 6.25 µM—final concen-
tration—calculated based on the estimated volume of blood using mouse weight) was 
administered via femoral artery and incubated for 5 min. Then, the distal 3 mm segment 
of the tail tip was dissected using a scalpel blade and the tail tip was placed in sterile saline 
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at 37 °C and the time taken to cessation of bleeding was measured up to 20 min at which 
point the assay was terminated. 
4.10. LDH Cytotoxicity Assay 
LDH cytotoxicity assay was performed using Pierce LDH Cytotoxicity Assay Kit 
(Thermo Fisher, UK) according to our optimized protocols for platelets. Human isolated 
platelets were incubated with various concentrations of 1,8-cineole or a positive control (a 
detergent provided in the kit) for 5 min. To this, the reaction mixture (provided in the kit) 
was added and incubated for 30 min at 37 °C. Following incubation, a stop solution that 
was also provided in the kit was added to terminate the reaction and the absorbance of 
this mixture was read at 490 nm and 650 nm using spectrophotometer (Molecular devices, 
UK). 
4.11. Immunoblotting Analysis 
SDS-PAGE and immunoblotting analyses were performed using standard protocols 
[56–58]. Human isolated platelets were treated with different concentrations of 1,8-cineole 
and a vehicle control [0.01% (v/v) ethanol] for 5 min and an agonist was added to trigger 
platelet activation. After 5 min, the activation was stopped by adding reducing sample 
treatment buffer and the obtained platelet lysates were used for SDS-PAGE followed by 
immunoblotting experiments with various antibodies. The mouse anti-human 14-3-3ζ an-
tibody (Santa Cruz Biotechnology, USA) was used to detect the protein, 14-3-3ζ as a load-
ing control in immunoblots. The Cy5-conjugated goat anti-rabbit and anti-mouse IgG 
were used as secondary antibodies in these experiments. 
4.12. Quantification of cAMP Levels in Platelets 
The cAMP levels in platelets were quantified using cAMP ELISA quantification kit 
(Enzo Life sciences, UK) according to the manufacturer’s instructions. Human isolated 
platelets were treated with a vehicle control or different concentrations of 1,8-cineole prior 
to measuring the level of cAMP using a cAMP ELISA kit. The amount of cAMP was quan-
tified using the standard curve which was plotted using the control samples provided in 
the kit. 
4.13. Statistical Analysis 
All the data are represented as mean ± SEM. The statistical significance was deter-
mined using one-way ANOVA except for the tail bleeding assay where the data were 
analysed using a non-parametric Kruskal–Wallis test. All the statistical analyses were per-
formed using GraphPad Prism 7 software (GraphPad Software Inc., USA). 
5. Conclusions 
In conclusion, essential oils extracted from medicinal plants have been extensively 
used for the treatment of various diseases and they are becoming as alternative therapeu-
tics worldwide [5,6]. 1,8-cineole has been used for many years for it is anti-inflammatory 
and antioxidant effects [12]. Several studies have shown that 1,8-cineole is effective and 
safe in the treatment of several diseases such bronchitis and inflammatory conditions [12]. 
Indeed, the clinical grade 1,8-cineole has been approved as a drug to treat some of these 
conditions. The results obtained in this study demonstrate that 1,8-cineole has potent in-
hibitory effects on human platelet function in isolated platelets, PRP (in the presence of 
plasma proteins) and in whole blood. As low as 6.25 µM may be sufficient to reduce un-
warranted platelet activation in the circulation. Therefore, 1,8-cineole could be beneficial 
in preventing and treating thrombotic diseases. Further studies to investigate the thera-
peutic potential and safety profile of 1,8-cineole in humans may aid in the design and 
development of novel anti-thrombotic strategies using this compound as a source or 
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template. Due to its numerous beneficial effects and pharmacological properties, this may 
be used as a safe and effective anti-thrombotic agent to control thrombotic diseases. 
Author Contributions: Conceptualization, K.A.A., D.R., D.W., and S.V.; methodology, K.A.A., D.R., 
A.P.B., A.R.S., D.W., and S.V.; software, K.A.A., D.R., A.P.B., K.P., and S.V.; validation, K.A.A., D.R., 
D.W., K.P., and S.V.; formal analysis, K.A.A., D.R., A.P.B., and S.V.; investigation, K.A.A., D.R., 
P.H.P., A.P.B., A.R.S., D.W., and S.V.; resources, S.V.; data curation, K.A.A., D.R., P.H.P., A.P.B., 
A.R.S., D.W., and S.V.; writing—original draft preparation, K.A.A., D.R., and S.V.; writing—review 
and editing, K.A.A., and S.V.; visualization, K.A.A., and S.V.; supervision, D.W., and S.V.; project 
administration, S.V.; funding acquisition, K.A.A. and S.V. All authors have read and agreed to the 
published version of the manuscript. 
Funding: This research was funded by the University of Albaha, Saudi Arabia and the British Heart 
Foundation (Grant numbers: PG/16/64/32311 and PG/19/62/34593). 
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the 
design of the study; in the collection, analyses, or interpretation of data; in the writing of the manu-
script, or in the decision to publish the results. 
References 
1. Gibbins, J.M. Platelet adhesion signalling and the regulation of thrombus formation. J. Cell Sci. 2004, 117, 3415–3425, 
doi:10.1242/jcs.01325. 
2. Barrett, N.E.; Holbrook, L.; Jones, S.; Kaiser, W.J.; Moraes, L.A.; Rana, R.; Sage, T.; Stanley, R.G.; Tucker, K.L.; Wright, B.; et al. 
Future innovations in anti-platelet therapies. Br. J. Pharmacol. 2008, 154, 918–939, doi:10.1038/bjp.2008.151. 
3. Cragg, G.M.; Newman, D.J. Natural products: A continuing source of novel drug leads. Biochim. Biophys. Acta BBA-Gen. Subj. 
2013, 1830, 3670–3695, doi:10.1016/j.bbagen.2013.02.008. 
4. Dhifi, W.; Bellili, S.; Jazi, S.; Bahloul, N.; Mnif, W. Essential Oils’ Chemical Characterization and Investigation of Some Biological 
Activities: A Critical Review. Medicines 2016, 3, 25, doi:10.3390/medicines3040025. 
5. Dagli, N.; Dagli, R.J.; Mahmoud, R.S.; Baroudi, K. Essential oils, their therapeutic properties, and implication in dentistry: A 
review. J. Int. Soc. Prev. Community Dent. 2015, 5, 335–340, doi:10.4103/2231-0762.165933. 
6. Burt, S. Essential oils: Their antibacterial properties and potential applications in foods—A review. Int. J. Food Microbiol. 2004, 
94, 223–253, doi:10.1016/j.ijfoodmicro.2004.03.022. 
7. Reis, D.; Jones, T. Aromatherapy: Using Essential Oils as a Supportive Therapy. Clin. J. Oncol. Nurs. 2017, 21, 16–19, 
doi:10.1188/17.cjon.16-19. 
8. Edris, A.E. Pharmaceutical and therapeutic Potentials of essential oils and their individual volatile constituents: A review. Phy-
tother. Res. 2007, 21, 308–323, doi:10.1002/ptr.2072. 
9. Dhakad, A.K.; Pandey, V.V.; Beg, S.; Rawat, J.M.; Singh, A. Biological, medicinal and toxicological significance of Eucalyptus 
leaf essential oil: A review. J. Sci. Food Agric. 2018, 98, 833–848, doi:10.1002/jsfa.8600. 
10. Sadlon, A.E.; Lamson, D.W. Immune-modifying and antimicrobial effects of Eucalyptus oil and simple inhalation devices. Altern. 
Med. Rev. A J. Clin. Ther. 2010, 15, 33–47. 
11. Brown, S.K.; Garver, W.S.; Orlando, R.A. 1,8-cineole: An Underappreciated Anti-inflammatory Therapeutic. J. Biomol. Res. Ther. 
2017, 06, 1–6, doi:10.4172/2167-7956.1000154. 
12. Seol, G.H.; Kim, K.Y. Eucalyptol and its role in chronic diseases. In Drug Discovery from Mother Nature; Gupta, S.C., Prasad, S., 
Aggarwal, B.B., Eds.; Springer: Houston, TX, USA, 2016; pp. 389–398. 
13. Juergens, U.; Dethlefsen, U.; Steinkamp, G.; Gillissen, A.; Repges, R.; Vetter, H. Anti-inflammatory activity of 1.8-cineol (euca-
lyptol) in bronchial asthma: A double-blind placebo-controlled trial. Respir. Med. 2003, 97, 250–256, doi:10.1053/rmed.2003.1432. 
14. Juergens, U.R.; Engelen, T.; Racké, K.; Stöber, M.; Gillissen, A.; Vetter, H. Inhibitory activity of 1,8-cineol (eucalyptol) on cytokine 
production in cultured human lymphocytes and monocytes. Pulm. Pharmacol. Ther. 2004, 17, 281–287, 
doi:10.1016/j.pupt.2004.06.002. 
15. Greiner, J.F.-W.; Müller, J.; Zeuner, M.-T.; Hauser, S.; Seidel, T.; Klenke, C.; Grunwald, L.-M.; Schomann, T.; Widera, D.; Sudhoff, 
H.; et al. 1,8-Cineol inhibits nuclear translocation of NF-κB p65 and NF-κB-dependent transcriptional activity. Biochim. Biophys. 
Acta BBA-Bioenerg. 2013, 1833, 2866–2878, doi:10.1016/j.bbamcr.2013.07.001. 
16. Shattil, S.J.; Kashiwagi, H.; Pampori, N. Integrin signaling: The platelet paradigm. Blood 1998, 91, 2645–2657. 
17. Nieswandt, B.; Varga-Szabo, D.; Elvers, M. Integrins in platelet activation. J. Thromb. Haemost. 2009, 7, 206–209, 
doi:10.1111/j.1538-7836.2009.03370.x. 
18. White, J.G.; Estensen, R.D. Degranulation of Discoid Platelets. Am. J. Pathol. 1972, 68, 289–302. 
19. Blair, P.; Flaumenhaft, R. Platelet α-granules: Basic biology and clinical correlates. Blood Rev. 2009, 23, 177–189, 
doi:10.1016/j.blre.2009.04.001. 
20. Whiteheart, S. Platelet granules: Surprise packages. Blood 2011, 118, 1190–1191, doi:10.1182/blood-2011-06-359836. 
Cells 2021, 10, 2616 21 of 22 
 
 
21. Varga-Szabo, D.; Braun, A.; Nieswandt, B. Calcium signaling in platelets. J. Thromb. Haemost. 2009, 7, 1057–1066, 
doi:10.1111/j.1538-7836.2009.03455.x. 
22. Durrant, T.N.; van den Bosch, M.T.; Hers, I. Integrin αIIbβ3 outside-in signaling. Blood 2017, 130, 1607–1619, doi:10.1182/blood-
2017-03-773614. 
23. Shen, B.; Delaney, M.K.; Du, X. Inside-out, outside-in, and inside–outside-in: G protein signaling in integrin-mediated cell ad-
hesion, spreading, and retraction. Curr. Opin. Cell Biol. 2012, 24, 600–606, doi:10.1016/j.ceb.2012.08.011. 
24. Broos, K.; Feys, H.; De Meyer, S.; Vanhoorelbeke, K.; Deckmyn, H. Platelets at work in primary hemostasis. Blood Rev. 2011, 25, 
155–167, doi:10.1016/j.blre.2011.03.002. 
25. Patel, R.V.; Mistry, B.M.; Shinde, S.K.; Syed, R.; Singh, V.; Shin, H.-S. Therapeutic potential of quercetin as a cardiovascular 
agent. Eur. J. Med. Chem. 2018, 155, 889–904, doi:10.1016/j.ejmech.2018.06.053. 
26. Li, Y.; Yao, J.; Han, C.; Yang, J.; Chaudhry, M.T.; Wang, S.; Liu, H.; Yin, Y. Quercetin, Inflammation and Immunity. Nutrients 
2016, 8, 167, doi:10.3390/nu8030167. 
27. Kerimi, A.; Williamson, G. The cardiovascular benefits of dark chocolate. Vasc. Pharmacol. 2015, 71, 11–15, 
doi:10.1016/j.vph.2015.05.011. 
28. Carnevale, R.; Loffredo, L.; Nocella, C.; Bartimoccia, S.; Bucci, T.; De Falco, E.; Peruzzi, M.; Chimenti, I.; Biondi-Zoccai, G.; 
Pignatelli, P.; et al. Epicatechin and Catechin Modulate Endothelial Activation Induced by Platelets of Patients with Peripheral 
Artery Disease. Oxidative Med. Cell. Longev. 2014, 2014, 691015, doi:10.1155/2014/691015. 
29. Vaiyapuri, S.; Ali, M.S.; Moraes, L.A.; Sage, T.; Lewis, K.R.; Jones, C.I.; Gibbins, J.M. Tangeretin Regulates Platelet Function 
through Inhibition of Phosphoinositide 3-Kinase and Cyclic Nucleotide Signaling. Arter. Thromb. Vasc. Biol. 2013, 33, 2740–2749, 
doi:10.1161/atvbaha.113.301988. 
30. Vaiyapuri, S.; Roweth, H.; Ali, M.S.; Unsworth, A.; Stainer, A.; Flora, G.; Crescente, M.; Jones, C.; Moraes, L.A.; Gibbins, J.M. 
Pharmacological actions of nobiletin in the modulation of platelet function. Br. J. Pharmacol. 2015, 172, 4133–4145, 
doi:10.1111/bph.13191. 
31. Jayakumar, T.; Lin, K.-C.; Lu, W.-J.; Lin, C.-Y.; Pitchairaj, G.; Li, J.-Y.; Sheu, J.-R. Nobiletin, a citrus flavonoid, activates vasodi-
lator-stimulated phosphoprotein in human platelets through non-cyclic nucleotide-related mechanisms. Int. J. Mol. Med. 2016, 
39, 174–182, doi:10.3892/ijmm.2016.2822. 
32. Harb, A.A.; Bustanji, Y.K.; Almasri, I.M.; Abdalla, S.S. Eugenol Reduces LDL Cholesterol and Hepatic Steatosis in Hypercho-
lesterolemic Rats by Modulating TRPV1 Receptor. Sci. Rep. 2019, 9, 14003, doi:10.1038/s41598-019-50352-4. 
33. Yasni, S.; Imaizumi, K.; Sin, K.; Sugano, M.; Nonaka, G.; Sidik. Identification of an active principle in essential oils and hexane-
soluble fractions of Curcuma xanthorrhiza Roxb. Showing triglyceride-lowering action in rats. Food Chem. Toxicol. 1994, 32, 273–
278, doi:10.1016/0278-6915(94)90200-3. 
34. Ballabeni, V.; Tognolini, M.; Chiavarini, M.; Impicciatore, M.; Bruni, R.; Bianchi, A.; Barocelli, E. Novel antiplatelet and an-
tithrombotic activities of essential oil from Lavandula hybrida Reverchon “grosso”. Phytomedicine 2004, 11, 596–601, 
doi:10.1016/j.phymed.2004.01.002. 
35. Chen, S.-J.; Wang, M.-H.; Chen, I.-J. Antiplatelet and calcium inhibitory properties of eugenol and sodium eugenol acetate. Gen. 
Pharmacol. Vasc. Syst. 1996, 27, 629–633, doi:10.1016/0306-3623(95)02089-6. 
36. Howard, M.; Hill, J.; Galluppi, G.; McLean, M. Plasma Protein Binding in Drug Discovery and Development. Comb. Chem. High 
Throughput Screen. 2010, 13, 170–187, doi:10.2174/138620710790596745. 
37. Wright, B.; Gibson, T.; Spencer, J.; Lovegrove, J.A.; Gibbins, J. Platelet-Mediated Metabolism of the Common Dietary Flavonoid, 
Quercetin. PLoS ONE 2010, 5, e9673, doi:10.1371/journal.pone.0009673. 
38. Janssens, J.; Laekeman, G.M.; Pieters, L.A.; Totte, J.; Herman, A.G.; Vlietinck, A.J. Nutmeg oil: Identification and quantitation 
of its most active constituents as inhibitors of platelet aggregation. J. Ethnopharmacol. 1990, 29, 179–188, doi:10.1016/0378-
8741(90)90054-w. 
39. Srivastava, K.; Justesen, U. Inhibition of platelet aggregation and reduced formation of thromboxane and lipoxygenase products 
in platelets by oil of cloves. Prostaglandins Leukot. Med. 1987, 29, 11–18, doi:10.1016/0262-1746(87)90092-8. 
40. Grice, I.D.; Rogers, K.L.; Griffiths, L. Isolation of Bioactive Compounds That Relate to the Anti-Platelet Activity of Cymbopogon 
ambiguus. Evid.-Based Complement. Altern. Med. 2011, 2011, 467134, doi:10.1093/ecam/nep213. 
41. Raghavendra, R.; Naidu, K.A. Spice active principles as the inhibitors of human platelet aggregation and thromboxane biosyn-
thesis. Prostaglandins Leukot. Essent. Fat. Acids 2009, 81, 73–78, doi:10.1016/j.plefa.2009.04.009. 
42. Aslan, J.E.; Itakura, A.; Gertz, J.M.; Mccarty, O.J.T. Platelet Shape Change and Spreading. Adv. Struct. Saf. Stud. 2011, 788, 91–
100, doi:10.1007/978-1-61779-307-3_7. 
43. Ravishankar, D.; Salamah, M.; Attina, A.; Pothi, R.; Vallance, T.; Javed, M.; Williams, H.F.; Alzahrani, E.M.S.; Kabova, E.; 
Vaiyapuri, R.; et al. Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis 
with enhanced efficacy. Sci. Rep. 2017, 7, 5738, doi:10.1038/s41598-017-05936-3. 
44. Tucker, K.L.; Sage, T.; Gibbins, J.M. Clot retraction. In Platelets and Megakaryocytes; Springer: Berlin/Heidelberg, Germany, 2012; 
pp. 101–107. 
45. Ballabeni, V.; Tognolini, M.; Bertoni, S.; Bruni, R.; Guerrini, A.; Rueda, G.M.; Barocelli, E. Antiplatelet and antithrombotic activ-
ities of essential oil from wild Ocotea quixos (Lam.) Kosterm. (Lauraceae) calices from Amazonian Ecuador. Pharmacol. Res. 
2007, 55, 23–30, doi:10.1016/j.phrs.2006.09.009. 
Cells 2021, 10, 2616 22 of 22 
 
 
46. Tognolini, M.; Ballabeni, V.; Bertoni, S.; Bruni, R.; Impicciatore, M.; Barocelli, E. Protective effect of Foeniculum vulgare essential 
oil and anethole in an experimental model of thrombosis. Pharmacol. Res. 2007, 56, 254–260, doi:10.1016/j.phrs.2007.07.002. 
47. Pinto, N.V.; Assreuy, A.M.S.; Coelho-De-Souza, A.N.; Ceccatto, V.M.; Magalhães, P.J.C.; Lahlou, S.; Leal-Cardoso, J.H. Endo-
thelium-dependent vasorelaxant effects of the essential oil from aerial parts of Alpinia zerumbet and its main constituent 1,8-
cineole in rats. Phytomedicine 2009, 16, 1151–1155, doi:10.1016/j.phymed.2009.04.007. 
48. Rayes, J.; Watson, S.P.; Nieswandt, B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J. Clin. Inves-
tig. 2019, 129, 12–23, doi:10.1172/jci122955. 
49. Suzuki-Inoue, K.; Hughes, C.; Inoue, O.; Kaneko, M.; Cuyun-Lira, O.; Takafuta, T.; Watson, S.; Ozaki, Y. Involvement of Src 
kinases and PLCγ2 in clot retraction. Thromb. Res. 2007, 120, 251–258, doi:10.1016/j.thromres.2006.09.003. 
50. Kim, S.; Jin, J.; Kunapuli, S.P. Akt Activation in Platelets Depends on Gi Signaling Pathways. J. Biol. Chem. 2004, 279, 4186–4195, 
doi:10.1074/jbc.m306162200. 
51. Murata, S.; Ogawa, K.; Matsuzaka, T.; Chiba, M.; Nakayama, K.; Iwasaki, K.; Kurokawa, T.; Sano, N.; Tanoi, T.; Ohkohchi, N. 
1,8-Cineole Ameliorates Steatosis of Pten Liver Specific KO Mice via Akt Inactivation. Int. J. Mol. Sci. 2015, 16, 12051–12063, 
doi:10.3390/ijms160612051. 
52. Murata, S.; Shiragami, R.; Kosugi, C.; Tezuka, T.; Yamazaki, M.; Hirano, A.; Yoshimura, Y.; Suzuki, M.; Shuto, K.; Ohkohchi, N.; 
et al. Antitumor effect of 1, 8-cineole against colon cancer. Oncol. Rep. 2013, 30, 2647–2652, doi:10.3892/or.2013.2763. 
53. Bruchhage, K.-L.; Koennecke, M.; Drenckhan, M.; Plötze-Martin, K.; Pries, R.; Wollenberg, B. 1,8-cineol inhibits the Wnt/β-
catenin signaling pathway through GSK-3 dephosphorylation in nasal polyps of chronic rhinosinusitis patients. Eur. J. Pharma-
col. 2018, 835, 140–146, doi:10.1016/j.ejphar.2018.07.060. 
54. Kim, K.Y.; Lee, H.S.; Seol, G.H. Eucalyptol suppresses matrix metalloproteinase-9 expression through an extracellular signal-
regulated kinase-dependent nuclear factor-kappa B pathway to exert anti-inflammatory effects in an acute lung inflammation 
model. J. Pharm. Pharmacol. 2015, 67, 1066–1074, doi:10.1111/jphp.12407. 
55. Salamah, M.F.; Ravishankar, D.; Kodji, X.; Moraes, L.A.; Williams, H.F.; Vallance, T.; Albadawi, D.A.; Vaiyapuri, R.; Watson, K.; 
Gibbins, J.; et al. The endogenous antimicrobial cathelicidin LL37 induces platelet activation and augments thrombus formation. 
Blood Adv. 2018, 2, 2973–2985, doi:10.1182/bloodadvances.2018021758. 
56. Jones, C.I.; Sage, T.; Moraes, L.A.; Vaiyapuri, S.; Hussain, U.; Tucker, K.L.; Barrett, N.E.; Gibbins, J.M. Platelet Endothelial Cell 
Adhesion Molecule-1 Inhibits Platelet Response to Thrombin and von Willebrand Factor by Regulating the Internalization of 
Glycoprotein Ib via AKT/Glycogen Synthase Kinase-3/Dynamin and Integrin αIIbβ3. Arter. Thromb. Vasc. Biol. 2014, 34, 1968–
1976, doi:10.1161/atvbaha.114.304097. 
57. Elashry, M.; Collins-Hooper, H.; Vaiyapuri, S.; Patel, K. Characterisation of connective tissue from the hypertrophic skeletal 
muscle of myostatin null mice. J. Anat. 2012, 220, 603–611, doi:10.1111/j.1469-7580.2012.01503.x. 
58. Vaiyapuri, S.; Sage, T.; Rana, R.H.; Schenk, M.P.; Ali, M.S.; Unsworth, A.; Jones, C.; Stainer, A.; Kriek, N.; Moraes, L.A.; et al. 
EphB2 regulates contact-dependent and contact-independent signaling to control platelet function. Blood 2015, 125, 720–730, 
doi:10.1182/blood-2014-06-585083. 
